Refametinib
Refametinib (RDEA119) is a potent and selective, ATP-noncompetitive inhibitor of MEK1 and MEK2 kinases, exhibiting IC50 values of 19 nM and 47 nM, respectively. It is widely used in cancer research, demonstrating antitumor activity in both in vitro cellular assays and in vivo models of various malignancies.
Product Specifications
CAS Number
923032-37-5
Product Name Alternative
Tumor, RDEA119, RDEA-119, Refametinib, RDEA 119, MAP2K, MAPKK, MEK, MEK1, MEK2, Inhibitor, inhibit, Mitogen-activated protein kinase kinase, orally, BAY 869766, BAY 86-97661, BAY869766, BAY-869766, allosteric
Field of Research
Signal Transduction
Purity
99.53% (May vary between batches)
Solubility
Ethanol:93 mg/mL (162.49 mM) ; DMSO:150 mg/mL (262.08 mM) ; H2O:< 1 mg/mL (insoluble or slightly soluble)
Smiles
S (NC1=C (NC2=C (F) C=C (I) C=C2) C (F) =C (F) C=C1OC) (=O) (=O) C3 (C[C@@H] (CO) O) CC3
Molecular Formula
C19H20F3IN2O5S
Molecular Weight
572.34
Storage Conditions
-20°C
Notes
For research use only.
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
